Subscribe | Email Us | CFP Books | Letters to the Editor
About us
"WE BELIEVE"
100% Freshly-Extracted All-Natural Health Juice








Caruba: Professional Writing Services



Costa Rica Homes for Sale



Pursuant to Title 17 U.S.C. 107, other copyrighted work is provided for educational purposes, research, critical comment, or debate without profit or payment. If you wish to use copyrighted material from this site for your own purposes beyond the 'fair use' exception, you must obtain permission from the copyright owner.

Views are those of authors and not necessarily those of Canada Free Press. Content is Copyright 1997-2014 the individual authors.

Site Copyright 1997-2014 Canada Free Press.Com Privacy Statement


Powered by ExpressionEngine



AMF-26

Development of the first way to make large amounts of promising anti-cancer substance

Author
- American Chemical Society By Isamu Shiina, Ph.D.  Wednesday, January 16, 2013
| Print friendly | Email Us

Scientists are reporting development of the first practical way to make large amounts of a promising new anti-cancer substance that kills cancer cells differently than existing medicines. Their article on synthesis of the substance, and tests demonstrating its effectiveness in the laboratory, appears in ACS’ Journal of Medicinal Chemistry.

Isamu Shiina and colleagues explain that the substance, AMF-26, showed promise against certain forms of cancer in laboratory studies, fostering excitement about its potential for development as a new anti-cancer drug. That excitement centered on AMF-26’s action in targeting a structure in cells, the Golgi apparatus, that had never been exploited in the past. The Golgi apparatus sorts and modifies hormones, enzymes and other key proteins for transport elsewhere. However, AMF-26 had been available in only small amounts by semisynthesis starting from AMF-14, which was extracted from the common soil mold of the genus Trichoderma.

Their report describes the first successful practical synthesis of AMF-26 and laboratory tests showing that the synthetic AMF-26 is just as effective as its natural counterpart. “The large-scale production of AMF-26 and its derivatives for the development of novel anticancer drugs are now in progress in this laboratory,” the report states.

The authors acknowledge funding from Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan.

Total Synthesis of AMF-26, an Antitumor Agent for Inhibition of the Golgi System, Targeting ADP-Ribosylation Factor 1

American Chemical Society, ACS is a congressionally chartered independent membership organization which represents professionals at all degree levels and in all fields of chemistry and sciences that involve chemistry.

Learn more about ACS.